Mylan Inc.
NASDAQ: MYL
$15.86
+$0.00 (+0.0%)
Closing Price on November 19, 2020
MYL Articles
Deutsche Bank provided a list of the major companies in the benchmark S&P 500 index that are not based in the United States. We cross-referenced the list with the Merrill Lynch research data base...
Published:
24/7 Wall St. covers many of each morning’s key analyst upgrades and downgrades. After a second look, it turns out that some key analyst calls are driving some of the more active American...
Published:
Last Updated:
Thursday's top analyst upgrades, downgrades and initiations include Bankrate, Eli Lilly, Embraer, Oracle and Southwest Airlines.
Published:
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V. (NASDAQ: MYL)....
Published:
S&P Capital IQ released a report regarding the performance of companies in terms of earnings and revenue.
Published:
Back in November of 2010, 24/7 Wall St. first issued a list of stocks to own for the next decade. Even long-term investors need to assess their portfolios from time to time.
Published:
If there was ever a time for investors to be concerned about valuations, it might be now. With the market trading at over 18 times earnings, things are getting a little pricey.
Published:
Teva Pharmaceutical Industries has just approached Mylan with a public takeover bid valued at $82 per share in cash and stock.
Published:
Independent research firm Argus has weighed in on Mylan and Perrigo prior to the acquisition.
Published:
Friday's top analyst upgrades, downgrades and initiations include Apple, Citrix Systems, Kythera Biopharmaceuticals, Mylan, Netflix and Weatherford International.
Published:
Generic drug maker Mylan has proposed to acquire rival Perrigo for $205 per share in cash and stock.
Published:
Last Updated:
Mylan has announced that it will have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion.
Published:
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
Published:
ThinkstockMonday after the markets closed, Mylan, Inc. (NASDAQ: MYL) reported its fourth-quarter financial results as in line with estimates. Specifically the company had $1.05 in earnings per share...
Published:
Last Updated:
What are investors, and patients, supposed to think when is launching a generic version of Diovan?
Published:
Last Updated: